# OnCo record rosewood (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/rosewood/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "rosewood", "NCT03332017" ;
  schema:name "ROSEWOOD"@en ;
  schema:alternateName "Zanubrutinib plus obinutuzumab in follicular lymphoma"@en, "ROSEWOOD trial"@en ;
  schema:description "Adding a targeted tablet to an antibody roughly doubled the chance of the lymphoma shrinking and tripled the time before it grew again, in people whose follicular lymphoma had already returned twice."@en ;
  schema:url <https://onco.cc/trials/rosewood/> ;
  schema:dateModified "2026-10-01"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03332017>, <https://doi.org/10.1200/JCO.23.00775> ;
  onco:status "positive" ;
  onco:tag "lymphoma-evidence" ;
  onco:phase "2" ;
  schema:startDate "2017-11-14" ;
  onco:cancers <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/btk/>, <https://onco.cc/targets/cd20/> ;
  onco:drugs <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/obinutuzumab/> ;
  onco:pathways <https://onco.cc/pathways/bcr-signalling/> ;
  onco:terms <https://onco.cc/terms/orr/>, <https://onco.cc/terms/complete-response/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-combination-space/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-rosewood-zanubrutinib-obinutuzumab-follicular-jco-2023/> .